Current treatment of glioblastoma in the elderly includes surgery, radiotherapy and chemotherapy, but the prognosis remains extremely poor, and its optimal management is still debated. Longer survival after extensive resection compared with biopsy only has been reported, although the survival advantage remains modest. Radiation in the form of standard (60 Gy in 30 fractions over 6 weeks) and abbreviated courses of radiotherapy (30–50 Gy in 6–20 fractions over 2–4 weeks) has been employed in elderly patients with glioblastoma, showing survival benefits compared with supportive care alone. Temozolomide is an alkylating agent recently employed in older patients with newly diagnosed glioblastoma. The addition of concomitant and/or adjuvant chemotherapy with temozolomide to radiotherapy, which is currently the standard treatment in adults with glioblastoma, is emerging as an effective therapeutic option for older patients with favorable prognostic factors. The potential benefits on survival, improvement in quality of life and toxicity of different schedules of radiotherapy plus temozolomide need to be addressed in future randomized studies. Free full text available at www.tumorionline.it
ParkinD.M.: Global cancer statistics in the year 2000. Lancet Oncol, 2: 533–543, 2001.
2.
Cancer Facts & Figures 2005, In: Surveillance Research, pp 1–60, American Cancer Society, Atlanta, 2005.
3.
JukichP.J., McCarthyB.J., SurawiczT.S., FreelsS., DavisF.G.: Trends in incidence of primary brain tumors in the United States, 1985–1994. Neuro Oncol, 3: 141–151, 2001.
4.
JohannesenT.B., Angell-AndersenE., TretliS., LangmarkF., LoteK.: Trends in incidence of brain and central nervous system tumors in Norway, 1970–1999. Neuroepidemiology, 23: 101–111, 2004.
5.
ChakrabartiI., CockburnM., CozenW., WangY.P., Preston-MartinS.: A population-based description of glioblastoma multiforme in Los Angeles County, 1974–1999. Cancer, 104: 2798–2806, 2005.
6.
DavisF.G., FreelsS., GrutschJ., BarlasS., BremS.: Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991. J Neurosurg, 88: 1–10, 1998.
7.
GreigN.H., RiesL.G., YancikR., RapoportS.I.: Increasing annual incidence of primary malignant brain tumors in the elderly. J Natl Cancer Inst, 82: 1621–1624, 1990.
8.
MaoY., DesmeulesM., SemenciwR.M., HillG., GaudetteL., WigleD.T.: Increasing brain cancer rates in Canada. Can Med Assoc J, 145: 1583–1591, 1991.
9.
SimpsonJ.R., HortonJ., ScottC., CurranW.J., RubinP., FischbachJ., IsaacsonS., RotmanM., AsbellS.O., NelsonJ.S.: Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys, 26: 239–244, 1993.
10.
LawsE.R., ShaffreyM.E., MorrisA., Anderson FAJ.r.: Surgical management of intracranial gliomas — does radical resection improve outcome?Acta Neurochir Suppl, 85: 47–53, 2003.
11.
KelesG.E., AndersonB., BergerM.S.: The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol, 52: 371–379, 1999.
12.
LacroixM., Abi-SaidD., FourneyD.R., GokaslanZ.L., ShiW., DeMonteF., LangF.F., McCutcheonI.E., HassenbuschS.J., HollandE., HessK., MichaelC., MillerD., SawayaR.: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg, 95: 190–198, 2001.
13.
BrownP.D., MaurerM.J., RummansT.A., PollockB.E., BallmanK.V., SloanJ.A., BoeveB.F., ArusellR.M., ClarkM.M., BucknerJ.C.: A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery, 57: 495–504, 2005.
14.
MitchellP., EllisonD.W., MendelowA.D.: Surgery for malignant gliomas: mechanistic reasoning and slippery statistics. Lancet Neurol, 4, 413–422, 2005.
MineoJ.F., BordronA., BaronciniM., RamirezC., MaurageC.A., BlondS., Dam-HieuP.: Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients. Acta Neurochir (Wien), 149: 245–252, 2007.
17.
SanaiN., BergerM.S.: Glioma extent of resection and its impact on patient outcome. Neurosurgery, 62: 753–764, 2008.
18.
StummerW., ReulenH.J., MeinelT., PichlmeierU., SchumacherW., TonnJ.C., RohdeV., OppelF., TurowskiB., WoiciechowskyC., FranzK., PietschT.; ALA-Glioma Study Group: Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery, 62, 564–576, 2008.
19.
StummerW., PichlmeierU., MeinelT., WiestlerO.D., ZanellaF., ReulenH.J.; ALA-Glioma Study Group: ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol, 7: 392–401, 2006.
20.
VuorinenV., HinkkaS., FärkkiläM., JääskeläinenJ.: Debulking or biopsy of malignant glioma in elderly people — a randomised study. Acta Neurochir (Wien), 145: 5–10, 2003.
21.
KellyP.J., HuntC.: The limited value of cytoreductive surgery in elderly patients with malignant gliomas. Neurosurgery, 34: 62–66, 1994.
22.
QuigleyM.R., MaroonJ.C.: The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas. Neurosurgery, 29: 385–388, 1991.
23.
HessK.R.: Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol, 42: 227–231, 1999.
24.
VivesK.P., PiepmeierJ.M.: Complications and expected outcome of glioma surgery. J Neurooncol, 42: 289–302, 1999.
25.
MetcalfeS.E., GrantR.: Biopsy versus resection for malignant glioma. Cochrane Database Syst Rev, 3: CD002034, 2001.
26.
BaumanG.S., GasparL.E., FisherB.J., HalperinE.C., MacdonaldD.R., CairncrossJ.G.: A prospective study of short course RT in poor prognosis glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 29: 835–839, 1994.
27.
FordJ.M., StenningS.P., BooteD.J., CounsellR., FalkS.J., FlavinA., LaurenceV.M., BleehenN.M.: A short fractionation radiotherapy treatment for poor prognosis patients with high grade glioma. Clin Oncol (R Coll Radiol), 9: 20–24, 1997.
28.
HoeglerD.B., DaveyP.: A prospective study of short course radiotherapy in elderly patients with malignant glioma. J Neurooncol, 33: 201–214, 1997.
29.
MohanD.S., SuhJ.H., PhanJ.L., KupelianP.A., CohenB.H., BarnettG.H.: Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary care institution. Int J Radiat Oncol Biol Phys, 42: 981–987, 1998.
30.
VillàS., ViñolasN., VergerE., YayaR., MartínezA., GilM., MorenoV., CaralL., GrausF.: Efficacy of radiotherapy for malignant gliomas in elderly patients. Int J Radiat Oncol Biol Phys, 42: 977–980, 1998.
31.
PiergaJ.Y., Hoang-XuanK., FeuvretL., SimonJ.M., CornuP., BailletF., MazeronJ.J., DelattreJ.Y.: Treatment of malignant gliomas in the elderly. J Neurooncol, 43: 187–193, 1999.
32.
BrandesA.A., VastolaF., BassoU.: A prospective study in glioblastoma multiforme. Cancer, 3: 657–662, 2003.
33.
GlantzM., ChamberlainM., LiuQ., LitofskyN.S., RechtL.D.: Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer, 97: 2262–2266, 2003.
RoaW., BrasherP.M.A., BaumanG., AnthesM., BrueraE., ChanA., FisherB., FultonD., GulavitaS., HaoC., HusainS., MurthaA., PetrukK., StewartD., TaiP., UrtasunR., CairncrossJ.G., ForsythP.: Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol, 22: 1593–1598, 2004.
36.
MarijnenC.A., van den BergS.M., van DuinenS.G., VoormolenJ.H., NoordijkE.M.: Radiotherapy is effective in patients with glioblastoma multiforme with a limited prognosis and in patients above 70 years of age: a retrospective single institution analysis. Radiother Oncol, 75: 210–216, 2005.
37.
Keime-GuiberF., ChinotO., TaillandierL., Cartalat-CarelS., FrenayM., KantorG., GuillamoJ.S., JadaudE., ColinP., BondiauP.Y., MeneïP., LoiseauH., BernierV., HonnoratJ., BarriéM., MokhtariK., MazeronJ.J., BisseryA., DelattreJ.Y.; Association of French-Speaking Neuro-Oncologists: Radiotherapy for glioblastoma in the elderly. N Engl J Med, 356: 1527–1535, 2007.
38.
ThomasR., JamesN., GuerreroD., AshleyS., GregorA., BradaM.: Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma. Radiother Oncol, 33: 113–116, 1994.
39.
WhittleI.R., BasuN., GrantR., WalkerM., GregorA.: Management of patients aged >60 years with malignant glioma: good clinical status and radiotherapy determine outcome. Br J Neurosurg, 16: 343–347, 2002.
40.
LaperriereN., ZurawL., CairncrossG.: Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol, 64: 259–273, 2002.
41.
BleehenN.M., StenningS.P.: A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer, 64: 769–774, 1991.
42.
ChinotO.L., BarrieM., FraugerE., DufourH., Figarella-BrangerD., PalmariJ., BraguerD., Hoang-XuanK., MoktariK., PeragutJ-CC, MartinP-MM, GrisoliF.: Phase II study of zemozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly population. Cancer, 100: 2208–2214, 2004.
43.
ChamberlainM.C., ChalmersL.: A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma. J Neurooncol, 82: 207–209, 2007.
44.
StuppR., MasonW., Van der BentM., WellerM., FisherB., TaphoornM.J., BelangerK., BrandesA.A., MarosiC., BogdahnU., CurschmannJ., JanzerR.C., LudwinS.K., GorliaT., AllgeierA., LacombeD., CairncrossJ.G., EisenhauerE., MirimanoffR.O.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 352: 987–996, 2005.
45.
MinnitiG., De SanctisV., MuniR., FilipponeF., BozzaoA., ValerianiM., OstiM.F., De PaulaU., LanzettaG., TomboliniV., Maurizi EnriciR.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol, 88: 97–103, 2008.
46.
SijbenA.E., McIntyreJ.B., RoldánG.B., EasawJ.C., YanE., ForsythP.A., ParneyI.F., MaglioccoA.M., BernsenH., CairncrossJ.G.: Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. J Neurooncol, 89: 97–103, 2008.
47.
CombsS.E., WagnerJ., BischofM., WelzelT., WagnerF., DebusJ., Schulz-ErtnerD.: Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys, 70: 987–992, 2008.
48.
PiccirilliM., BistazzoniS., GagliardiF.M., LandiA., SantoroA., GiangasperoF., SalvatiM.: Treatment of glioblastoma multiforme in elderly patients. Clinico-therapeutic remarks in 22 patients older than 80 years. Tumori, 92: 98–103, 2006.
49.
MinnitiG., De SanctisV., MuniR., RasioD., LanzettaG., BozzaoA., OstiM.F., SalvatiM., ValerianiM., CantoreG.P., Maurizi EnriciR.: Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J Neurooncol, 91: 95–100, 2009.
50.
BrandesA.A., FranceschiE., TosoniA., BeneventoF., ScopeceL., MazzocchiV., BacciA., AgatiR., CalbucciF., ErmaniM.: Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer, 115: 3512–3518, 2009.
51.
MaireJ.P., CoudinB., GuérinJ., CaudryM.: Neuropsychologic impairment in adults with brain tumors. Am J Clin Oncol, 10: 156–162, 1987.
52.
StylopoulosL.A., GeorgeA.E., de LeonM.J., MillerJ.D., FooS.H., HiesigerE., WiseA.: Longitudinal CT study of parenchymal brain changes in glioma survivors. Am J Neuroradiol, 9: 517–522, 1988.
53.
GrantR., LiangB.C., PageM.A., CraneD.L., GreenbergH.S., JunckL.: Age influences chemotherapy response in astrocytomas. Neurology, 45: 929–933, 1995.
54.
GilbertM., O'NeillA., GrossmanS., GrunnetM., MehtaM., JubelirerS., HellmanR.: A phase II study of preradiation chemotherapy followed by external beam radiotherapy for the treatment of patients with newly diagnosed glioblastoma multiforme: an Eastern Cooperative Oncology Group study (E2393). J Neurooncol, 47: 145–152, 2000.
55.
HegiM.E., DiserensA.C., GorliaT., HamouM.F., de TriboletN., WellerM., KrosJ.M., HainfellnerJ.A., MasonW., MarianiL., BrombergJ.E., HauP., MirimanoffR.O., CairncrossJ.G., JanzerR.C., StuppR.: MGMT gene silencing and benefit from temozolomidein glioblastoma. N Engl J Med, 352: 997–1003, 2005.
56.
GorliaT., van den BentM.J., HegiM.E., MirimanoffR.O., WellerM., CairncrossJ.G., EisenhauerE., BelangerK., BrandesA.A., AllgeierA., LacombeD., StuppR.: Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981–22981/CE.3. Lancet Oncol, 9; 29–38, 2008.
LouisD.N.: Molecular pathology of malignant gliomas. Annu Rev Pathol, 1: 97–117, 2006.
59.
RichJ.N., ReardonD.A., PeeryT., DowellJ.M., QuinnJ.A., PenneK.L., WikstrandC.J., Van DuynL.B., DanceyJ.E., McLendonR.E., KaoJ.C., StenzelT.T., Ahmed RasheedB.K., Tourt-UhligS.E., HerndonJ.E.2nd, VredenburghJ.J., SampsonJ.H., FriedmanA.H., BignerD.D., FriedmanH.S.: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol, 22: 133–142, 2004.
60.
PradosM.D., LambornK.R., ChangS., BurtonE., ButowskiN., MalecM., KapadiaA., RabbittJ., PageM.S., FedoroffA., XieD., KelleyS.K.: Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol, 8: 67–78, 2006.
61.
PradosM.D., YungW.K., WenP.Y., JunckL., CloughesyT., FinkK., ChangS., RobinsH.I., DanceyJ., KuhnJ.: Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemother Pharmacol, 61: 1059–1067, 2008.
62.
MellinghoffI.K., WangM.Y., VivancoI., Haas-KoganD.A., ZhuS., DiaE.Q., LuK.V., YoshimotoK., HuangJ.H., ChuteD.J., RiggsB.L., HorvathS., LiauL.M., CaveneeW.K., RaoP.N., BeroukhimR., PeckT.C., LeeJ.C., SellersW.R., StokoeD., PradosM., CloughesyT.F., SawyersC.L., MischelP.S.: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med, 353: 2012–2024, 2005.
Haas-KoganD.A., PradosM.D., TihanT., EberhardD.A., JellumaN., ArvoldN.D., BaumberR., LambornK.R., KapadiaA., MalecM., BergerM.S., StokoeD.: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst, 97: 880–887, 2005.
65.
BrownP.D., KrishnanS., SarkariaJ.N., WuW., JaeckleK.A., UhmJ.H., GeoffroyF.J., ArusellR., KitangeG., JenkinsR.B., KuglerJ.W., MortonR.F., RowlandK.M.Jr., MischelP., YongW.H., ScheithauerB.W., SchiffD., GianniniC., BucknerJ.C.; North Central Cancer Treatment Group Study N0177: Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol, 26: 5603–5609, 2008.
66.
PradosM.D., ChangS.M., ButowskiN., DeBoerR., ParvataneniR., CarlinerH., KabuubiP., Ayers-RinglerJ., RabbittJ., PageM., FedoroffA., SneedP.K., BergerM.S., McDermottM.W., ParsaA.T., VandenbergS., JamesC.D., LambornK.R., StokoeD., Haas-KoganD.A.: Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol, 27: 579–584, 2009.
VredenburghJ.J., DesjardinsA., HerndonJ.E.2nd, DowellJ.M., ReardonD.A., QuinnJ.A., RichJ.N., SathornsumeteeS., GururanganS., WagnerM., BignerD.D., FriedmanA.H., FriedmanH.S.: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res, 13: 1253–1259, 2007.
69.
AliS.A., McHaylehW.M., AhmadA., SehgalR., BraffetM., RahmanM., BejjaniG., FriedlandD.M.: Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. J Neurosurg, 109: 268–272, 2008.
70.
DesjardinsA., ReardonD.A., HerndonJ.E.2nd, MarcelloJ., QuinnJ.A., RichJ.N., SathornsumeteeS., GururanganS., SampsonJ., BaileyL., BignerD.D., FriedmanA.H., FriedmanH.S., VredenburghJ.J.: Bevacizumab Plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res, 14: 7068–7073, 2008.
71.
LaiA., FilkaE., McGibbonB., NghiemphuP.L., GrahamC., YongW.H., MischelP., LiauL.M., BergsneiderM., PopeW., SelchM., CloughesyT.: Phase II pilot study of bevacizumabin combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys, 71: 1372–1380, 2008.
72.
ReardonD.A., FinkK.L., MikkelsenT., CloughesyT.F., O'NeillA., PlotkinS., GlantzM., RavinP., RaizerJ.J., RichK.M., SchiffD., ShapiroW.R., Burdette-RadouxS., DropchoE.J., WittemerS.M., NippgenJ., PicardM., NaborsL.B.: Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol, 26(34): 5610–5617, 2008.
73.
StuppR., GoldbrunnerB., NeynsB., SchlegelU., ClementP., GrabenbauerG.G., HegiM.E., NippgenJ., PicardM., WellerM.: Phase I/II trial of celingitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients with newly diagnosed glioblastoma (GBM). J Clin Oncol (Meeting Abstracts), 2007; 25: 2000.
StuppR., HegiM.E., GilbertM.R., ChakravartiA.: Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol, 25: 4127–4136, 2007.
